title: Non-Hodgkin's lymphomas, version 4.2014.
abstract: Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Mantle cell lymphoma (MCL) accounts for approximately 6% of all newly diagnosed NHL cases. Radiation therapy with or without systemic therapy is a reasonable approach for the few patients who present with early-stage disease. Rituximab-based chemoimmunotherapy followed by high-dose therapy and autologous stem cell rescue (HDT/ASCR) is recommended for patients presenting with advanced-stage disease. Induction therapy followed by rituximab maintenance may provide extended disease control for those who are not candidates for HDT/ASCR. Ibrutinib, a Bruton tyrosine kinase inhibitor, was recently approved for the treatment of relapsed or refractory disease. This manuscript discusses the recommendations outlined in the NCCN Guidelines for NHL regarding the diagnosis and management of patients with MCL.
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Zelenetz
authors.forename: Leo I
authors.initials: LI
authors.lastname: Gordon
authors.forename: William G
authors.initials: WG
authors.lastname: Wierda
authors.forename: Jeremy S
authors.initials: JS
authors.lastname: Abramson
authors.forename: Ranjana H
authors.initials: RH
authors.lastname: Advani
authors.forename: C Babis
authors.initials: CB
authors.lastname: Andreadis
authors.forename: Nancy
authors.initials: N
authors.lastname: Bartlett
authors.forename: John C
authors.initials: JC
authors.lastname: Byrd
authors.forename: Myron S
authors.initials: MS
authors.lastname: Czuczman
authors.forename: Luis E
authors.initials: LE
authors.lastname: Fayad
authors.forename: Richard I
authors.initials: RI
authors.lastname: Fisher
authors.forename: Martha J
authors.initials: MJ
authors.lastname: Glenn
authors.forename: Nancy Lee
authors.initials: NL
authors.lastname: Harris
authors.forename: Richard T
authors.initials: RT
authors.lastname: Hoppe
authors.forename: Steven M
authors.initials: SM
authors.lastname: Horwitz
authors.forename: Christopher R
authors.initials: CR
authors.lastname: Kelsey
authors.forename: Youn H
authors.initials: YH
authors.lastname: Kim
authors.forename: Susan
authors.initials: S
authors.lastname: Krivacic
authors.forename: Ann S
authors.initials: AS
authors.lastname: LaCasce
authors.forename: Auayporn
authors.initials: A
authors.lastname: Nademanee
authors.forename: Pierluigi
authors.initials: P
authors.lastname: Porcu
authors.forename: Oliver
authors.initials: O
authors.lastname: Press
authors.forename: Rachel
authors.initials: R
authors.lastname: Rabinovitch
authors.forename: Nishitha
authors.initials: N
authors.lastname: Reddy
authors.forename: Erin
authors.initials: E
authors.lastname: Reid
authors.forename: Ayman A
authors.initials: AA
authors.lastname: Saad
authors.forename: Lubomir
authors.initials: L
authors.lastname: Sokol
authors.forename: Lode J
authors.initials: LJ
authors.lastname: Swinnen
authors.forename: Christina
authors.initials: C
authors.lastname: Tsien
authors.forename: Julie M
authors.initials: JM
authors.lastname: Vose
authors.forename: Joachim
authors.initials: J
authors.lastname: Yahalom
authors.forename: Nadeem
authors.initials: N
authors.lastname: Zafar
authors.forename: Mary
authors.initials: M
authors.lastname: Dwyer
authors.forename: Hema
authors.initials: H
authors.lastname: Sundar
mesh_terms: D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis* / Q000628:therapy*; D009367:Neoplasm Staging; D012008:Recurrence